These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16728929)

  • 1. Preventing excessive bleeding in patients with von Willebrand disease.
    Gill JC
    Clin Adv Hematol Oncol; 2006 Mar; 4(3):207-9. PubMed ID: 16728929
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.
    Rivard GE; Aledort L;
    Haemophilia; 2008 Mar; 14(2):271-5. PubMed ID: 18194310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding management of uterine conization using a pasteurized FVIII/VWF Concentrate in a woman affected by type 2A von willebrand disease.
    Lapecorella M; Napoletano M; Mariani G; Mascaretti G; Colageo E
    Clin Appl Thromb Hemost; 2009; 15(2):245-6. PubMed ID: 18160560
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical experience of prophylactic treatment in von Willebrand disease.
    Lethagen S
    Thromb Res; 2006; 118 Suppl 1():S9-11. PubMed ID: 16616322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of von Willebrand's disease.
    Logan LJ
    Prog Clin Biol Res; 1990; 324():279-90. PubMed ID: 2106690
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of bleeding disorders in adults.
    Peyvandi F; Klamroth R; Carcao M; Federici AB; DI Minno G; Jiménez-Yuste V; Rodriguez Merchán EC
    Haemophilia; 2012 May; 18 Suppl 2():24-36. PubMed ID: 22530576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired von Willebrand syndrome.
    Alvarez MT; Jimenez-Yuste V; Gracia J; Quintana M; Hernandez-Navarro F
    Haemophilia; 2008 Jul; 14(4):856-8. PubMed ID: 18445010
    [No Abstract]   [Full Text] [Related]  

  • 12. Osteoid osteoma in a child with severe von Willebrand disease.
    Petratos D; Matsinos G; Pergantou H; Anastasopoulos J; Platokouki H
    Haemophilia; 2010 May; 16(3):557-9. PubMed ID: 19930471
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
    Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of von Willebrand disease and its clinical implications.
    Haematologica; 2004 Sep; 89(9):1036. PubMed ID: 15377463
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of a hemorrhagic syndrome in severe von Willebrand disease in the presence of circulating anti-von-Willebrand-factor antibody].
    Monteagudo J; López Guillermo A; Castillo R
    Med Clin (Barc); 1988 May; 91(1):28-30. PubMed ID: 3139944
    [No Abstract]   [Full Text] [Related]  

  • 17. von Willebrand disease in the 21st century: current approaches and new challenges.
    Mannucci PM; Federici AB; James AH; Kessler CM
    Haemophilia; 2009 Sep; 15(5):1154-8. PubMed ID: 19624761
    [No Abstract]   [Full Text] [Related]  

  • 18. Prophylaxis in von Willebrand disease.
    Franchini M; Targher G; Lippi G
    Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal and fetal outcomes in pregnancies affected by von Willebrand disease type 2.
    Burlingame J; McGaraghan A; Kilpatrick S; Hambleton J; Main E; Laros RK
    Am J Obstet Gynecol; 2001 Jan; 184(2):229-30. PubMed ID: 11174508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the management of von Willebrand disease.
    Federici AB
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):29-30. PubMed ID: 18322438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.